What is OpAns?
OpAns is a specialized provider of bioanalytical and clinical diagnostics services, recognized for its innovative solutions tailored to workplace drug testing and the justice system. At the core of its offerings is the patented amasse device, which facilitates highly efficient micro-sampling for the precise analysis of steroid hormones, biomarkers, and other critical compounds. Serving a broad spectrum of clients including clinics, healthcare providers, and payors, OpAns emphasizes personalized testing protocols and stringent compliance adherence. With a legacy spanning over two decades, the company is dedicated to refining analytical methodologies to meet diverse application requirements.
How much funding has OpAns raised?
OpAns has raised a total of $482K across 2 funding rounds:
Debt
$150K
Debt
$332K
Debt (2020): $150K with participation from PPP
Debt (2021): $332K led by PPP
Key Investors in OpAns
PPP
Public-Private Partnership
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for OpAns?
The substantial capital infusion, particularly the recent strategic investment, positions OpAns for accelerated growth and expanded market penetration. This late-stage funding is likely to fuel further development of its proprietary technologies, enhance its service delivery infrastructure, and potentially broaden its client base into new verticals. Strategic utilization of this financing will be key to solidifying OpAns's leadership in the competitive diagnostics landscape and capitalizing on emerging opportunities in personalized medicine and forensic analysis.
See full OpAns company page
